The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average. Those on 6 mg dropped 5.5% while placebo takers slimmed down 2.2% (just over 5 pounds).

GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity. This comprehensive review explores the mechanisms, clinical implications,

Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site will, too.